
This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.

This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Eric Simpson discussing the concept of disease modification and the benefits of early intervention when treating patients with AD. Dr. Simpson also reviews available data investigating the impacts of therapies for AD on the disease itself and on associated comorbidities.

In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson discusses key considerations for disease modification and the importance of early intervention in treating patients with AD.

Join experts Drs. Amy Paller and Peter Lio at an educational symposium as they investigate atopic dermatitis as a risk factor for the development of food allergies. The speakers will also discuss the benefits of early intervention in pediatric atopic dermatitis and the potential for disease modification.

Dr Kwatra poses the question: How do we assess disease modification in PN, and can treating early stop tissue damage and worsening of systemic diseases associated with PN?

This video presentation of the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands features Dr. Stephan Weidinger, Dr. Eric Simpson, and Dr. Marjolein de Bruin-Weller. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating patients with AD early in the disease course, and the emerging real-world data on the use of advanced systemic therapies for patients with AD.

This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.
